Janssen Pharmaceutica Nv

Nalin L Subasinghe

Zhihua Sui

James C Lanter

Thomas P Markotan

Jeremy Mark Travins

Mark James Wall

Kristi A Leonard

Maxwell David Cummings

Christopher M Flores

Shelley K Ballentine

Michael Peter Winters

Heather Rae Hufnagel

Ehab Khalil

Farah Ali

Joan M Gushue

Xuqing Zhang

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

Benzo-fused heterocyclic derivatives useful as agonists of GPR120

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: 

Substituted pyrazoles as N-type calcium channel blockers

The present invention comprises compounds of Formula I. wherein: R, R, R, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Cyclohexyl-azetidinyl antagonists of CCR2

The present invention comprises compounds of Formula (I). wherein: R, R, R, R, X, Y, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2

The present invention relates to compounds of Formula (I), wherein X, X, X, X, R, R, R, and Q are as defined herein, useful as N-type calcium channel blockers.

Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein R, R, and Rare as defined in the specification, as are A Z, Q, Rand R.

Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions

Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein R, R, and Rare defined in the specification, as are A Z, Q, Rand R.

Growing community of inventors

Exton, PA, United States of America

Nalin L Subasinghe